AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard long-term therapy
Description: The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
Study NCT05605548 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A look-alike inactive substance, a sugar pill
Study NCT04759313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Image Narrative
Description: Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
Study NCT05877703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: close kinetic chain exercises
Description: CKC include mini squats, leg press, step-up and step-down, wall slides etc along with their respective modality as quadriceps drill and static cycle ergometer respectively on grade-3 knee OA patients
Study NCT05877703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: open kinetic chain exercises
Description: The distal segment of the body components can move freely during OKC exercise.OKC exercises include quadriceps setting, knee extension in sitting and straight leg raise in lying position; it also includes quadriceps drills as part of OKC exercises
Study NCT05320380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD123 ADC IMGN632
Description: Given IV
Study NCT05320380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration/biopsy
Study NCT05320380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV
Study NCT05320380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT and IV
Study NCT05320380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT05320380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT05320380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT
Study NCT05320380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT05320380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT05484466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-H1505R
Description: There are three groups in this study. ZM-H1505R will be used in group A and Group B ，Subjects can use it for 48 weeks Group A: 30 subjects； ZM-H1505R 50 mg QD +ZM-H1505R placebo； Group B: 30 subjects； ZM-H1505R 100 mg QD
Study NCT05320380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study NCT05320380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given IT
Study NCT06015568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-129: 1500mg or 2000mg IV Q2W
Description: Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs
Study NCT06015568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befotertinib: 75 mg or 100 mg Po QD
Description: The initial dose of Befotertinib is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD.~Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs.
Study NCT04598230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants randomized to this arm will receive up to 20 sessions of evidence based cognitive behavioral therapy (CBT) of extended duration, with more exposure tasks and greater family involvement than has been studied in the past.
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX and standard long-term radiotherapy
Description: FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
Study NCT04598230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination therapy (COMB)
Description: Participants randomized to this arm will receive cognitive behavioral therapy comparable to that in the cognitive behavioral therapy arm, plus one of three selective serotonin reuptake inhibitors (SSRI) medications (fluoxetine, sertraline, escitalopram)
Study NCT04875182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of Delirium development
Description: Postoperative pain scores of the patients will recorded by using a numerical rating scale.
Study NCT05690698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quatiapine
Description: Atypical antipsychotic
Study NCT05690698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Antipsychotic
Study NCT05720767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: HMPL-523 is a selective small-molecule SYK inhibitor.
Study NCT05720767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole is an FDA approved synthetic triazole antifungal agent
Study NCT05720767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state
Study NCT04864678 — intervention group
Intervention type: OTHER
Intervention: Referral to the Young People's Health Service immunisation nurse
Description: Young people who have been referred to an immunisation nurse at the Young People's Health Service.
Study NCT05082506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief.
Study NCT05082506 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acupressure
Description: Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief.
Study NCT05195268 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracardiac Catheter Ablation
Description: Both arms will receive intracardiac catheter ablation procedures as described.
Study NCT05195268 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intracardiac Catheter Ablation
Description: Both arms will receive intracardiac catheter ablation procedures as described.
Study NCT06326671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Inhalation Powder
Description: It's a generic product of Spiriva HandiHaler.
Study NCT06326671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva HandiHaler
Description: Tiotropium Bromide Inhalation Powder RLD, which binds to M3 receptors, and blocks the action of acetylcholine to relieve spasm of bronchial smooth muscle.
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX and standard long-term radiotherapy
Description: FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI and standard long-term radiotherapy
Description: FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
Study NCT06164613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinnamomum Verum oil extract
Description: one capsule of 1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days
Study NCT06164613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg PO Canola oil soft gel capsule
Study NCT05484466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZM-H1505R placebo
Description: There are three groups in this study. ZM-H1505R will be used in group A and Group C ，Subjects can use it for 48 weeks Group A: 30 subjects；ZM-H1505R 50 mg +ZM-H1505R placebo 50mg QD ； Group C: 30 subjects；ZM-H1505R placebo 100mg QD
Study NCT05484466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ZM-H1505R placebo
Description: There are three groups in this study. ZM-H1505R will be used in group A and Group C ，Subjects can use it for 48 weeks Group A: 30 subjects；ZM-H1505R 50 mg +ZM-H1505R placebo 50mg QD ； Group C: 30 subjects；ZM-H1505R placebo 100mg QD
Study NCT05484466 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Baraclude
Description: All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI and standard long-term radiotherapy
Description: FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU and standard long-term radiotherapy
Description: 5-FU and standard long-term radiotherapy based on organoids drug sensitivity
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU and standard long-term radiotherapy
Description: 5-FU and standard long-term radiotherapy based on organoids drug sensitivity
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU and pembrolizumab and standard long-term radiotherapy
Description: 5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU and pembrolizumab and standard long-term radiotherapy
Description: 5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other individualized treatments
Description: Other individualized treatments based on organoids drug sensitivity
Study NCT05484466 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Baraclude
Description: All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks
Study NCT04992546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRN473 (SAR444727)
Description: White to off-white gel suspension
Study NCT04992546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRN473 (SAR444727)
Description: White to off-white gel suspension
Study NCT04992546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White to off-white gel suspension
Study NCT04921852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: costoclavicular brachial plexus block
Description: A transverse scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed immediately below the midpoint of the clavicle and over the medial infraclavicular fossa. 20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected in to the middle of the three brachial plexus cords with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance .Readiness for surgery time will be evaluated after costoclavicular block.
Study NCT04921852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral sagittal infraclavicular block
Description: A sagittal scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed medial to the coracoid process to obtain a transverse view of the axillary artery.20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected posterior to the axillary artery near to the three cords of brachial plexus with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance.Readiness for surgery time will be evaluated after lateral sagittal infraclavicular block.
Study NCT05176951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil
Description: Oral inhalation using a capsule-based dry powder inhaler device.
Study NCT05176951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation using a capsule-based dry powder inhaler device.
Study NCT05019651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Wearable System
Description: Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear for 6 +/- 2 weeks. They will be asked to continue to wear the device until all study data is collected.
Study NCT04749563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IGC AD1
Description: IGC AD1 oral Solution
Study NCT04749563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of IGC AD1 oral Solution
Study NCT05439551 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MeMed BV®
Description: Patients Serum and Whole blood samples will be examined using the MeMed BV® test. Test results will have no impact on patient management.
Study NCT04941469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Specifically optimized off-the-counter foot orthosis (Medical grade foot orthosis)
Description: The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type. The original Formthotics (Original Dual Hard) is currently in use and is considered a Class A medical device according to the Health Science Authority of Singapore risk classification system. At the moment, the original Formthotics (Original Dual Hard) is also available in the retail market, abeit, without assessment guided optimisations for specific feet types.
Study NCT04941469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain off-the-counter foot orthosis (Medical grade foot orthosis)
Description: The control device for this study would be the plain original Formthotics (Original Dual Hard).
Study NCT06224907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec
Description: Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
Study NCT05793957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05793957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05793957 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Use smartphone
Study NCT05793957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Technology Intervention
Description: Use VR headset
Study NCT06403293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment (AH Plus-NA)
Description: Root canal treatment procedures explained in arm descriptions.
Study NCT06403293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment (AH Plus-EA)
Description: Root canal treatment procedures explained in arm descriptions.
Study NCT06403293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment (BC-NA)
Description: Root canal treatment procedures explained in arm descriptions.
Study NCT06403293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment (BC-EA)
Description: Root canal treatment procedures explained in arm descriptions.
Study NCT05759546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Parp inhibitor
Study NCT05759546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: CDK4/6 inhibitor
Study NCT05759546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalpiciclib
Description: CDK4/6 inhibitor
Study NCT05759546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant/AI
Description: Endocrine therapy
Study NCT05759546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant/AI
Description: Endocrine therapy
Study NCT05610722 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DreaMed Endo Digital
Description: The DreaMed Endo.Digital uses information gathered from glucose monitoring (sensor readings or capillary blood glucose measurements), insulin dosing and meal data during daily routine home care. Following a 5-minute data collection and analysis, the algorithm learns and suggests insulin dose adjustments and behavioral tips for optimization of glucose control. The algorithm is designed as an advisory tool for health care professionals.
Study NCT04853589 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel
Description: After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 1 will receive hyaluronic acid gel.
Study NCT04853589 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel + carrier
Description: After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 2 will receive hyaluronic acid gel together with a collagen carrier.
Study NCT05291572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: speech therapy only
Description: fluency shaping technique
Study NCT05291572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: chamber system using oxygen with pressure
Study NCT05291572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment
Description: brain stimulant
Study NCT05277116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genome Informed Risk Assessment (GIRA) report
Description: A Genome Informed Risk Assessment (GIRA) report that combines genetic (monogenic risks and polygenic risk scores), family history, and clinical risk information from participants.
Study NCT05352165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other individualized treatments
Description: Other individualized treatments based on organoids drug sensitivity
Study NCT06281327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding.~Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count >250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L.
Study NCT05070871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolyzed Collagen
Description: Hydrolyzed collagen type II derived from the bone powder of Norwegian Atlantic salmon.
Study NCT05070871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pure maltodextrin.
Study NCT05070871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CalGo
Description: CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and collagen type 2.
Study NCT05579275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCXH-212 Injection
Description: Based on the development principle of NCV, a community-type tumor neoantigen mRNA vaccine, JCXH-212 injection, has been developed that can be applied to patients with malignant solid tumors. NCVs activate tumor-specific CD4+ T cells and CD8+ T cells through active immunity, and these T cells can inhibit and kill tumor cells in cancer patients, thus prolonging the survival of cancer patients.
Study NCT04749472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sling
Description: Participants wore six different shoulder slings in a randomized order.
Study NCT05406063 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic multiple fraction radiotherapy